Currently, various pharmacological treatments for osteoporosis are proven to reduce fracture risks, including bisphosphonates, which inhibit bone resorption by osteoclasts; selective estrogen receptor modulators; the monoclonal antibody to the receptor activator of nuclear factor kappa-B ligand (RANKL); and a parathyroid hormone [9]. This evidence concerns the gene TNFSF11 and osteoporosis.